A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy
Clinical trial NCT04660344 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04660344
- Sponsor
- Hoffmann-La Roche
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-05-03
- Primary completion
- 2025-06-15
- Enrollment
- 761
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.